22 June 2021
Hybrid
Europe/Berlin timezone

Agenda

.

  • 9:45 - 10:00 // Welcome

    Welcome
    W. Weichert - spokesperson DKTK partner site Munich
    M. von Bergwelt - deputy spokesperson DKTK partner site Munich

  • 10:00 - 10:30 // DKTK Program: Molecularly Targeted Therapy

    Immunomodulatory drugs destabilize transmembrane proteins by interfering with HSP90 dependent quality control - Michael Heider
    ADAM10 - a novel therapeutic target for acute leukemia - Ehsan Bahrami (Young Scientist)
    Chair K. Spiekermann, F Bassermann

  • 10:30 - 11: 30 // Key Note

    Immune response against SARS-CoV-2 and implications for future vaccine developments

    Prof. Hans-Georg Rammensee (University of Tübingen)
    Chair: M. von Bergwelt

  • 11:30 - 12:00 // Joint Funding Talks (UPGRADE)

    TBA
    Chair: F. Klauschen

  • 11:45 - 12:30 // DKTK Program: Exploitation of Oncogenic Mechanisms

    Genome-wide in vivo screens link regulatory networks and phenotypic evolution in T-ALL - Anja Pfaus (Young Scientist)
    Characterization of the tumor microenvironment and dissection of cell-cell communication in molecular pancreatic cancer subtypes - Stefanie Bärthel (Young Scientist)
    14-3-3sigma functions as an intestinal tumor suppressor - Heiko Hermeking
    Chair: D. Saur, F. Klauschen

  • 14:00 - 14:30 // Cancer Core Structures in Munich

    BZKF Bayerisches Zentrum für Krebsforschung - Julia Mayerle
    CCCM Comprehensive Cancer Center München - Volker Heinemann
    SoO School of Oncology - TBA
    Chair: F. Bassermann

  • 14:30 - 15:00 // Key Note

    Tryptophan catabolism as a regulator of anti-tumor immunity

    Dr. Christiane Opitz (DKFZ Heidelberg)
    Chair: W. Weichert

  • 15:00 - 15:30 // DKTK Program: Radiation Oncology and Imaging

    Translation in Technology - High Precision Treatment and Innovative Treatment in Radiation Oncology - Denise Bernhardt
    Intrinsic Radioresistance and Heterogeneity in HNSCC Model Systems - Samet Mutlu (Young Scientist)

  • 15:30 - 16:00 // DKTK Program: Cancer Immunotherapy

    TCRs and off-the-shelf CAR T-cell therapy? - Tobias Feuchtinger
    Neoadjuvant therapy shapes the tumor immune landscape via downregulation of protumorigenic genes in myeloid cell subsets - Carmen Mota Reyes (Young Scientist)
    Chair: A. Krackhardt, S. Endres

  • 16:00 - 17:00 // Key Note

    Microbiota-Centered Interventions: principles and future

    Prof. Laurence Zitvogel (Gustave Roussy, Paris)
    Chair: S. Kobold

  • 17:00 - 17:15 // Closing Remarks and *Best Talk* Award

    W. Weichert - spokesperson DKTK partner site Munich
    M. von Bergwelt - deputy spokesperson DKTK partner site Munich